{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:08:17Z","timestamp":1790438897644,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["837004014"],"award-info":[{"award-number":["837004014"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["Vici grant 91814655"],"award-info":[{"award-number":["Vici grant 91814655"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1245\/s10434-019-07274-2","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T11:48:23Z","timestamp":1551700103000},"page":"3945-3952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy"],"prefix":"10.1245","volume":"26","author":[{"given":"Martine","family":"Bloemendal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"van Willigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalijn F.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes J.","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E. M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H. J. G.","family":"Aarntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger H. T.","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus J. M.","family":"van der Hoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"18","key":"7274_CR1","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042\u201347.","journal-title":"J Clin Oncol."},{"issue":"36","key":"7274_CR2","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u201306.","journal-title":"J Clin Oncol."},{"issue":"1","key":"7274_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejso.2006.10.032","volume":"33","author":"AC Akkooi van","year":"2007","unstructured":"van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33(1):102\u201308.","journal-title":"Eur J Surg Oncol."},{"issue":"26","key":"7274_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med."},{"issue":"26","key":"7274_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med."},{"issue":"20","key":"7274_CR6","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med."},{"issue":"9992","key":"7274_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet."},{"issue":"26","key":"7274_CR8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med."},{"issue":"4","key":"7274_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med."},{"issue":"1","key":"7274_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med."},{"issue":"19","key":"7274_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med."},{"issue":"19","key":"7274_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med."},{"issue":"19","key":"7274_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"19","key":"7274_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"key":"7274_CR15","unstructured":"EMEA\/H\/C\/003985 - PSUSA\/00010379\/201801 - Product information Opdivo. European Medicines Agency. Accessed November 2018."},{"key":"7274_CR16","unstructured":"EMA\/H\/C\/002604 - WS\/1274 - Product information Tafinlar. European Medicines Agency. Accessed November 2018."},{"key":"7274_CR17","unstructured":"EMA\/H\/C\/002643 - WS\/1274 - Product information Mekinist. European Medicines Agency. Accessed November 2018."},{"key":"7274_CR18","unstructured":"EMA\/CHMP\/706955\/2018 - CHMP post-authorisation summary of positive opinion for Keytrudy (II-47). European Medicines Agency. Accessed November 2018."},{"key":"7274_CR19","unstructured":"Full prescribing information Yervoy. Food and Drug Administration. Accessed November 2018."},{"key":"7274_CR20","unstructured":"Full prescribing information Opdivo. Food and Drug Administration. Accessed November 2018."},{"key":"7274_CR21","unstructured":"Full prescribing information Mekinist. European Medicines Agency. Accessed November 2018."},{"key":"7274_CR22","unstructured":"Full prescribing information Tafinlar. Food and Drug Administration. Accessed November 2018."},{"key":"7274_CR23","unstructured":"Full prescribing information Keytruda. Food and Drug Administration. Accessed November 2018."},{"issue":"6","key":"7274_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/SLA.0000000000000233","volume":"259","author":"NM Rueth","year":"2014","unstructured":"Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259(6):1215\u201322.","journal-title":"Ann Surg."},{"issue":"2","key":"7274_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129\u201342.","journal-title":"J Natl Cancer Inst."},{"issue":"23","key":"7274_CR26","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med."},{"issue":"4","key":"7274_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjsurg.2013.04.012","volume":"207","author":"JJ Baker","year":"2014","unstructured":"Baker JJ, Meyers MO, Frank J, Amos KD, Stitzenberg KB, Ollila DW. Routine restaging PET\/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. Am J Surg. 2014;207(4):549\u201354.","journal-title":"Am J Surg."},{"issue":"3","key":"7274_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","volume":"75","author":"S Podlipnik","year":"2016","unstructured":"Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol. 2016;75(3):516\u201324.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"7274_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/CMR.0000000000000347","volume":"27","author":"MF Madu","year":"2017","unstructured":"Madu MF, Timmerman P, Wouters M, van der Hiel B, van der Hage JA, van Akkooi ACJ. PET\/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. Melanoma Res. 2017;27(3):251\u201357.","journal-title":"Melanoma Res."},{"issue":"4","key":"7274_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1245\/s10434-017-5768-8","volume":"24","author":"TS Park","year":"2017","unstructured":"Park TS, Phan GQ, Yang JC, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24(4):947\u201351.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"7274_CR31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdy124","volume":"29","author":"J Lewin","year":"2018","unstructured":"Lewin J, Sayers L, Kee D, et al. Surveillance imaging with FDG-PET\/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018;29(7):1569\u201374.","journal-title":"Ann Oncol."},{"issue":"2","key":"7274_CR32","doi-asserted-by":"publisher","first-page":"e000317","DOI":"10.1136\/esmoopen-2017-000317","volume":"3","author":"KHJ Lim","year":"2018","unstructured":"Lim KHJ, Spain L, Barker C, et al. Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO Open. 2018;3(2):e000317.","journal-title":"ESMO Open."},{"key":"7274_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16833","author":"KHJ Podlipnik","year":"2018","unstructured":"Podlipnik S, Moreno-Ramirez D, Carrera C, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2018. \n                    https:\/\/doi.org\/10.1111\/bjd.16833\n                    \n                  .","journal-title":"Br J Dermatol."},{"issue":"5","key":"7274_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/CMR.0b013e3283480256","volume":"21","author":"RA Abbott","year":"2011","unstructured":"Abbott RA, Acland KM, Harries M, O\u2019Doherty M. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. Melanoma Res. 2011;21(5):446\u201349.","journal-title":"Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07274-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07274-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07274-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T19:17:15Z","timestamp":1583176635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07274-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["7274"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07274-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"WR.G. received speaker fees from Astellas, Bayer, Merck Sharp & Dohme (MSD), and the European Society for Medical Oncology, participated in advisory boards of Amgen, Bayer, Bristol-Myers Squibb, Curevac, Dendreon, IQVIA, Janssen-Cilag, Merck (MSD), Morphosys, and Sanofi, and received research grants from Astellas, Amgen, Bayer, Janssen-Cilaq, and Sanofi. R. H. T. K. has received speaker fees from BMS, MSD, and Roche. He has advisory relationships with BMS, MSD, Novartis, and Roche. He received research grants from BMS and Roche. For the remaining authors, no conflicts of interest are declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}